Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$16.22 USD
+0.28 (1.76%)
Updated May 13, 2024 04:00 PM ET
After-Market: $16.23 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CPRX 16.22 +0.28(1.76%)
Will CPRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Other News for CPRX
Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
Truist Financial Keeps Their Buy Rating on Catalyst Pharma (CPRX)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)
Catalyst Pharmaceuticals price target raised by $2 at H.C. Wainwright, here's why